OSTAAT™ is a non-invasive connected medical device designed for people affected by osteopenia or osteoporosis, with or without associated severe chronic kidney disease.
The technology involves applying a low-intensity electric current with no side effects. The current acts on cell membrane mechanisms, allowing calcium to enter the cells, thus promoting bone growth. The technology can be used preventively, to reduce the risk of fractures of all kinds, or curatively, to accelerate the healing process of fractures* caused by osteoporosis, severe chronic kidney disease, or other conditions. At the cutting edge of technology, the OSTAAT™ device in its prototype belt version for clinical studies and its smart clothing version, will be able to be activated via a mobile app accessible on cell phone, tablet, or computer.
*Claims will be addressed in future clinical trials.
Every year, millions of women over 50 are newly diagnosed with osteoporosis and immediately face a dangerous treatment gap. While medications exist, they take 6 to 12 months to begin working, and much longer to show meaningful effects at the hip, the most life-threatening fracture site. During this vulnerable period, patients remain at very high risk of fractures, with no effective short-term protection.
This situation is even more alarming when we consider that nearly 40% of patients refuse medication altogether, most often due to fear of side effects, according to a survey conducted in 2016 by the Bone Health & Osteoporosis Foundation. Among those who start treatment, over 50% will discontinue within one to two years.
OSTAAT™ technology was created to fill this critical and persistent gap, offering immediate, drug-free, non-invasive support for bone health starting at diagnosis.
OSTAAT™ also meets an urgent need in another overlooked population: the 850+ million people worldwide with chronic kidney disease (CKD), including 135 million with advanced CKD. These patients are at high risk of osteoporosis and fractures but are often excluded from pharmacologic treatment due to medical contraindications.
With no safe medication options, CKD patients are left unprotected, facing progressive bone loss, fragile bones, and increased mortality.
OSTAAT™ offers these patients a breakthrough solution, making it possible to proactively manage bone health without drugs.
OSTAAT™ fills a dangerous gap left wide open by conventional treatment.
It's not just an innovation. It's a lifesaving bridge to stronger bones…when patients need it most.
The OSTAAT™ device uses a sophisticated low-intensity electrical current to stimulate bone growth. This innovative and patented technology, the result of rigorous academic research, has undergone extensive studies to elucidate its mechanism of action on osteogenesis.
*Patents pending.
The scientific validation of OSTAAT™ is based on a comprehensive research program:
These multidimensional studies have demonstrated OSTAAT™'s potential as a non-pharmacological alternative for osteoporosis and bone disorders related to chronic kidney disease, particularly for patients intolerant to traditional drug treatments.
The discovery of a link between electrical stimulation and bone growth led to an exhaustive review of scientific literature, generating new hypotheses currently being studied in collaboration with university researchers.
An in vitro study, conducted in partnership with UQAM since August 2022, has confirmed the initial hypothesis on the link between electrical stimulation and bone formation. The results validate the device's voltage parameters, essential for stimulating ion channels responsible for calcium deposition in cells.
These advances will soon be presented at scientific conferences and published in international journals, marking a crucial step towards launching a multicenter clinical study.
OSTAAT™ technology represents a groundbreaking advancement in the treatment of osteopenia and osteoporosis with or without severe chronic kidney disease, offering a unique and innovative approach to bone health management.
By combining cutting-edge technology with a deep understanding of bone physiology, OSTAAT™ offers a safe, effective, and convenient alternative to traditional osteoporosis treatments.
OSTAAT™ technology shows promise in stimulating osteoblasts, counteracting osteoclast impact, and influencing H-type blood vessels crucial for bone homeostasis. This systematic approach aims to thoroughly validate this non-invasive bone growth technology, potentially offering a new treatment option for various bone-related conditions.
Our innovative approach to bone growth stimulation raised numerous questions regarding the effects of electrical stimulation on bone growth mechanisms. To address these, our scientific team conducted a comprehensive review of existing literature, identifying key areas for investigation.
Following this analysis, we initiated in vitro and ex vivo trials to elucidate and demonstrate the mechanisms of action of our OSTAAT™ technology. These preliminary investigations were designed to pave the way for future pilot and multicenter clinical trials, ultimately enabling us to validate the efficacy and safety of our device in human subjects.
Our trials focused on testing hypotheses formulated by our scientific team regarding the relationships between OSTAAT™ electrical stimulation and various bone-related processes:
Our scientists' hypotheses yielded promising results, suggesting that electrical stimulation OSTAAT™ at specific voltages influences cell membrane mechanisms, promoting calcium entry into bone cells and stimulating bone growth in a manner mimicking natural calcium influx pathways. These findings, currently confidential, will be the subject of forthcoming scientific publications.
The in vitro trials also addressed additional hypotheses, with results to be included in upcoming publications. This proof of concept has propelled us towards the next crucial phase: pilot and multicenter clinical trials involving patients with osteopenia, osteoporosis, or chronic kidney disease-related osteoporosis.
Preliminary results indicate a significant increase in bone mass using OSTAAT™, driving us towards more extensive clinical trials in collaboration with renowned institutions. Concurrently, we are exploring potential applications of our technology to support bone health in astronauts during extended space missions, offering a possible solution to bone density loss in microgravity environments.
Clinical Development of OSTAAT™ The clinical development of OSTAAT™ has followed a systematic approach, progressing from preliminary studies to planned human trials.
Current Focus: In Vitro and Ex Vivo Trials
Next Steps: Clinical Studies
Future Projects
These studies will validate our OSTAAT™ technology under various clinical conditions and explore its potential in cutting-edge fields such as space medicine.
Note: Submission of scientific articles for publication is scheduled for the first quarter of 2025. Detailed technical reports ("White Papers") are available upon request from our research team.
